CD47‐SIRPα blocking‐based immunotherapy: Current and prospective therapeutic strategies
R Bouwstra, T van Meerten… - Clinical and Translational …, 2022 - Wiley Online Library
Background The CD47‐signal regulatory protein alpha (SIRPα)'don't eat me'signalling axis
is perhaps the most prominent innate immune checkpoint to date. However, from initial …
is perhaps the most prominent innate immune checkpoint to date. However, from initial …
CD47‐SIRPα blocking‐based immunotherapy: Current and prospective therapeutic strategies.
R Bouwstra, T van Meerten… - Clinical & Translational …, 2022 - search.ebscohost.com
Background: The CD47‐signal regulatory protein alpha (SIRPα)'don't eat me'signalling axis
is perhaps the most prominent innate immune checkpoint to date. However, from initial …
is perhaps the most prominent innate immune checkpoint to date. However, from initial …
CD47-SIRPα blocking-based immunotherapy: Current and prospective therapeutic strategies
R Bouwstra, T van Meerten, E Bremer - Clinical and Translational …, 2022 - research.rug.nl
BACKGROUND: The CD47-signal regulatory protein alpha (SIRPα)'don't eat me'signalling
axis is perhaps the most prominent innate immune checkpoint to date. However, from initial …
axis is perhaps the most prominent innate immune checkpoint to date. However, from initial …
CD47-SIRPα blocking-based immunotherapy: Current and prospective therapeutic strategies.
R Bouwstra, T van Meerten, E Bremer - Clinical and Translational …, 2022 - europepmc.org
Background The CD47-signal regulatory protein alpha (SIRPα)'don't eat me'signalling axis
is perhaps the most prominent innate immune checkpoint to date. However, from initial …
is perhaps the most prominent innate immune checkpoint to date. However, from initial …
[HTML][HTML] CD47‐SIRPα blocking‐based immunotherapy: Current and prospective therapeutic strategies
R Bouwstra, T van Meerten… - Clinical and Translational …, 2022 - ncbi.nlm.nih.gov
Background The CD47‐signal regulatory protein alpha (SIRPα)'don't eat me'signalling axis
is perhaps the most prominent innate immune checkpoint to date. However, from initial …
is perhaps the most prominent innate immune checkpoint to date. However, from initial …
CD47-SIRPα blocking-based immunotherapy: Current and prospective therapeutic strategies
R Bouwstra, T van Meerten… - Clinical and Translational …, 2022 - search.proquest.com
Background The CD47-signal regulatory protein alpha (SIRPα)'don't eat me'signalling axis
is perhaps the most prominent innate immune checkpoint to date. However, from initial …
is perhaps the most prominent innate immune checkpoint to date. However, from initial …
CD47-SIRPα blocking-based immunotherapy: Current and prospective therapeutic strategies
R Bouwstra, T van Meerten… - Clinical and …, 2022 - pubmed.ncbi.nlm.nih.gov
Background The CD47-signal regulatory protein alpha (SIRPα)'don't eat me'signalling axis
is perhaps the most prominent innate immune checkpoint to date. However, from initial …
is perhaps the most prominent innate immune checkpoint to date. However, from initial …
[PDF][PDF] CD47-SIRPα blocking-based immunotherapy: Current and prospective therapeutic strategies
R Bouwstra, T van Meerten, E Bremer - core.ac.uk
Background: The CD47-signal regulatory protein alpha (SIRPα)'don't eat me'signalling axis
is perhaps the most prominent innate immune checkpoint to date. However, from initial …
is perhaps the most prominent innate immune checkpoint to date. However, from initial …